Viking Advances Oral VK2735 to Phase 3 as Planned; Financing and Tolerability Remain Key

What happened

Viking Therapeutics has initiated the pivotal Phase 3 program for oral VK2735, a milestone that was previously guided for the fourth quarter of 2026, aligning with the company's stated timeline after mixed Phase 2 results. Management is reportedly addressing the safety and tolerability concerns that surfaced in the Phase 2 VENTURE-Oral trial, where higher-dose cohorts showed elevated discontinuations despite up to 12.2% mean weight loss at week 13. The DeepValue master report had flagged oral tolerability as a key risk, particularly against the backdrop of Lilly's Foundayo approval, which reset the competitive bar for oral obesity drugs. While this initiation removes a near-term execution risk, the company still faces a financing overhang with its shelf registration expiring in July 2026 and a cash runway only through June 2027 at current burn rates. The stock, trading around $29.60, continues to price in successful late-stage execution without a margin of safety from cash flows, supporting a wait-and-see approach until more data on durability and financing clarity emerge.

Implication

For investors, the initiation of oral Phase 3 is a positive signal that management is executing on its stated timeline, reducing bear-case probability. However, the fundamental thesis remains unchanged because the pivotal trial will take years to read out, and near-term value creation still hinges on the injectable VANQUISH program and a credible financing strategy. The mixed Phase 2 results and the competitive pressure from Lilly's Foundayo mean oral VK2735 must demonstrate a clear tolerability advantage to capture meaningful market share, which is yet unproven. The company's cash position of $603 million and runway through June 2027 implies it will need additional capital before oral Phase 3 completion, making the shelf replacement and potential dilutive financing a key watch item. Until maintenance-dosing data in Q3 2026 and a financing reset provide more clarity, risk-adjusted returns favor waiting on the sidelines, with an attractive entry near $24 and trimming above $40.

Thesis delta

The initiation of Phase 3 oral VK2735 as guided removes a significant timeline risk and supports the base case scenario, modestly reducing the bear case probability from 30% to perhaps 25%. Nevertheless, the WAIT rating remains due to unresolved financing dependency and the need for oral tolerability data to compete with approved oral therapies. Conviction could increase if subsequent disclosures show strong tolerability and a durable financing plan.